Efficacy and effects of Ponatinib

Ponatinib was studied in a major study involving 449 patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who were intolerant or resistant to treatment with dasatinib and nilotinib, or who had the T315I mutation. In this study, ponatinib was not compared with other treatments.

Study results showed that ponatinib treatment produced clinically relevant responses in all patient groups, with approximately 54% of patients with chronic phase myeloid leukemia having a major cytogenetic response; About 58% of patients with myeloid leukemia had severe hematological reactions; among patients with blast myeloid leukemia, about 31% had severe hematological reactions; among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, about 41% had severe hematological reactions.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.